 MIAMI, Aug. 24, 2021 GLOBE NEWSWIRE -- Ehave, Inc., OTC Pink: EHVVF the Company, a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today that it has filed a Form 6-K with the SEC disclosing the Company entered into a Research Project Agreement with The University of Melbourne o gather data and bio-markers to target Hallucinogen Persisting Perception Disorder HPPD on July 2, 2021. 